Tipranavir: A Ritonavir-Boosted Protease InhibitorA Viewpoint by Dushyantha T. Jayaweera

被引：0
|
作者：
Dushyantha T. Jayaweera
机构：
[1] University of Miami,Division of Infectious Diseases, Department of Medicine
来源：
Drugs | 2005年 / 65卷
关键词：
Ritonavir; Salvage Therapy; Gastrointestinal Toxicity; Lopinavir; Pivotal Study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1678 / 1679
页数：1
相关论文
共 50 条
  • [41] Is Ritonavir-boosted Protease Inhibitors (PIs/r) monotherapy noninferior to classic combined antiretroviral therapy (cART)?
    Mikula, Tomasz
    Dabrowska, Magdalena
    Wiercinska-Drapalo, Alicja
    HIV & AIDS REVIEW, 2010, 9 (03): : 61 - 64
  • [42] Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors
    Barreiro, P
    Camino, N
    de Mendoza, C
    Valer, L
    Núñez, M
    Martín-Carbonero, L
    González-Lahoz, J
    Soriano, V
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) : 438 - 443
  • [43] !Hill A, !Moyle G.: Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.: HIV Med 2007; 8: 259-264.: Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients
    Llibre, J. M.
    Perez-Alvarez, N.
    HIV MEDICINE, 2007, 8 (08) : 568 - 570
  • [44] Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir
    Martinez, Esteban
    D'Albuquerque, Polyana M.
    Llibre, Josep M.
    Gutierrez, Felix
    Podzamczer, Daniel
    Antela, Antonio
    Berenguer, Juan
    Domingo, Pere
    Moreno, Xabier
    Perez, Ignacio
    Pich, Judit
    Gatell, Jose M.
    AIDS, 2012, 26 (18) : 2315 - 2326
  • [45] Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid Levels
    Hill, Andrew
    Sawyer, Will
    Gazzard, Brian
    HIV CLINICAL TRIALS, 2009, 10 (01): : 1 - 12
  • [46] Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study
    Blanco, Jose L.
    Rojas, Jhon
    de Lazzari, Elisa
    Inciarte, Alexy
    Subirana, Mar
    Callau, Pilar
    Martinez-Rebollar, Maria
    Laguno, Montserrat
    Mallolas, Josep
    de la Mora, Lorena
    Torres, Berta
    Gonzalez-Cordon, Ana
    Martinez, Esteban
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (07) : 1974 - 1979
  • [47] Treatment-emergent gag cleavage site mutations during virological failure of ritonavir-boosted protease inhibitors
    Garcia-Diaz, A.
    Fox, Z.
    Dragsted, U. B.
    Kjaer, J.
    Clumeck, N.
    Philips, A.
    Lundgren, J. D.
    Geretti, A. M.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A80 - A80
  • [48] Comparison of the Pharmacokinetics of Apricitabine in the Presence and Absence of Ritonavir-Boosted Tipranavir A Phase I, Open-Label, Controlled, Single-Centre Study
    Cox, Susan
    Southby, Justine
    Linet, Otto
    Tackwell, Karie
    Borin, Marie
    Perry, Kim
    CLINICAL DRUG INVESTIGATION, 2009, 29 (11) : 721 - 728
  • [49] Confirmed efficacy and safety of dual therapy based in lamivudine plus a ritonavir-boosted protease inhibitor in the clinical setting
    Fontecha-Ortega, Maria
    Munoz-Mendoza, Vanessa
    Gomez, Cristina
    Sanchez-Conde, Matilde
    Angel Rodriguez, Miguel
    Jesus Vivancos, Maria
    Luis Casado, Jose
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [50] Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women
    Barcellos, Teresa
    Natavio, Melissa
    Stanczyk, Frank Z.
    Luo, Dandan
    Jusko, William J.
    Bender, Nicole M.
    CONTRACEPTION, 2019, 100 (04) : 283 - 287
12345